GW’s next act

How GW Pharmaceuticals plans to follow up its successful launch of Epidiolex

As Epidiolex’s launch continues to ramp up, GW Pharmaceuticals’ next act will be to take the plunge with its cannabinoid platform into larger, more complex neurobehavioral indications, and even cancer.

Not surprisingly, the rise of GW Pharmaceuticals plc has followed that of Epidiolex cannabidiol, its first wholly owned commercial product. After 12 years on the London Stock Exchange, GW listed on NASDAQ in 2013, since when it has raised over $1.4 billion (see Figure: “GW Fundraising”).

Figure: GW fundraising

GW Pharmaceuticals plc (NASDAQ:GWPH) raised just over $100 million in the 12 years following its 2001 IPO on the London Stock Exchange. In 2013, the company raised $32.7 million through a NASDAQ listing, and went on to raise over $200 million in each of the following five years, with the total raised on NASDAQ now topping $1.4 billion. The capital infusion fueled GW’s

Read the full 1419 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers